OptimizeRx Co.(NDA) Rating Reiterated by Zacks (OPRX)
OptimizeRx Co.(NDA) (NASDAQ:OPRX)‘s stock had its “outperform” rating reiterated by Zacks in a research report issued to clients and investors on Wednesday, Stock Ratings News reports. They currently have a $3.50 price objective on the stock. Zacks‘ price objective suggests a potential upside of 221.10% from the stock’s previous close.
Zacks‘ analyst wrote, “The expectation is that sales should significantly ramp with growth in revenue from voucher printing – which should pick as SampleMD’s distribution is further expanded, especially as it relates to Allscripts, DrFirst and NewCrop. The additional functionality and integration into new solutions should also increase awareness, increase value to the end user, increase the physician base and utilization, help to increase the number of drugs promoted, and expand opportunities for further growth. OPRX’s business model is super scalable. OPRX was cash flow positive in Q4, full-year 2012 and 1H 2013. We look for revenue growth of 133% in 2013. Distribution growth numbers are very encouraging. Further revenue growth could mean earnings/EPS/cash flow really accelerate. We are maintaining our Outperform rating. “
Shares of OptimizeRx Co (NASDAQ:OPRX) traded up 0.92% during mid-day trading on Wednesday, hitting $1.10. 5,000 shares of the company’s stock traded hands. OptimizeRx Co has a 52-week low of $0.86 and a 52-week high of $2.05. The stock’s 50-day moving average is $1.37 and its 200-day moving average is $1.49. The company has a market cap of $15.7 million and a price-to-earnings ratio of 64.12.
OptimizeRx Corporation provides platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.